Table 1 Baseline characteristics of the two groups
From: Relationship between increased systemic immune-inflammation index and coronary slow flow phenomenon
CSFP group (n = 89) | Control group (n = 167) | p value | |
|---|---|---|---|
Age, years | 59.6 ± 5.6 | 58.5 ± 6.3 | 0.193 |
Male sex, n (%) | 56 (62.9) | 90 (53.9) | 0.165 |
BMI, kg/m2 | 25.4 ± 1.3 | 25.7 ± 2.1 | 0.160 |
Smoking, n (%) | 28 (31.5) | 43 (25.7) | 0.331 |
Hypertension, n (%) | 32 (36.0) | 40 (24.0) | 0.042 |
Diabetes mellitus, n (%) | 26 (29.2) | 30 (18.0) | 0.038 |
Calcium canal blocker, n (%) | 16 (18.0) | 27 (16.2) | 0.712 |
Beta-blocker, n (%) | 20 (22.5) | 32 (19.2) | 0.531 |
ACEI/ARB, n (%) | 13 (14.6) | 29 (17.4) | 0.570 |
Antiplatelet, n (%) | 22 (24.7) | 45 (26.9) | 0.699 |
Statin, n (%) | 20 (22.5) | 39 (23.4) | 0.873 |
Nitrates, n (%) | 12 (13.5) | 26 (15.6) | 0.655 |